RxDoctor Payments Data

Eric Lee, MD

Cardiovascular Disease · Glendale, CANPI 1982790812

Payments from drug & device makers

$108,315in general payments, 2019–2025

Across 817 payments — averaging $132.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Janssen Research & Development, LLC$87K
  • Biotronik NRO, Inc.$2K
  • Novartis$2K
  • Boston Scientific$2K
  • Amgen$1K
  • AstraZeneca$1K
  • plus $13K from 43 others

What the payments were for

  • Speaking & faculty fees$1251%
  • Travel & lodging$2,0099%
  • Food & beverage$19,00189%
  • Education$1010%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$108,315 in reported general payments places this provider in the 90th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$447,499
Medicare patients
1,199
Services billed
4,482

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban507$550,782
EntrestoSacubitril/Valsartan157$191,140
XareltoRivaroxaban105$129,987
JardianceEmpagliflozin93$117,861
FarxigaDapagliflozin Propanediol74$73,117
MultaqDronedarone Hcl28$45,918
VascepaIcosapent Ethyl32$27,609
Repatha SureclickEvolocumab33$21,295
VerquvoVericiguat17$17,073
Icosapent Ethyl28$11,465
EdarbyclorAzilsartan Med/Chlorthalidone22$9,249
Repatha PushtronexEvolocumab16$9,192
Telmisartan268$7,806
Metoprolol Succinate560$7,556
Atorvastatin Calcium739$6,230

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$1,282$550,782507 claims
NovartisEntresto$1,945$191,140157 claims
Johnson & JohnsonXarelto$650$129,987105 claims
Boehringer IngelheimJardiance$960$117,86193 claims
AstraZenecaFarxiga$1,313$73,11774 claims
Sanofi-aventis U.S. LLCMultaq$200$45,91828 claims
MerckVerquvo$1,088$17,07317 claims
Arbor Pharmaceuticals, Inc.Edarbyclor$149$9,24922 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Glendale

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →